Os melhores médicos para o tratamento de Cancro do cólon em estádio 4 no exterior — Página 2

O médico formou-se na Faculdade de Medicina da Universidade de Ancara e completou a residência em medicina interna na Faculdade de Medicina de Ancara GATA. Especializando-se em oncologia médica e hematologia, o médico completou uma bolsa clínica nos EUA. Pioneiro na Turquia, o médico fez parte da equipe que realizou o primeiro transplante de medula óssea no país. O médico atuou como professor visitante em instituições de prestígio em Londres e Suíça. Detentor do Certificado Europeu de Oncologia Médica, o médico é membro fundador tanto da Sociedade Turca de Oncologia Médica quanto do Grupo Oncológico Turco. O foco clínico inclui câncer de mama, gastrointestinal, pulmão, linfomas e mieloma.<\/p>

O Dr. Saban Sec especializa-se em cancros gastrointestinais, com investigação sobre o prognóstico e os resultados do tratamento do cancro do cólon.

• Especialista em oncologia médica com foco em cancros do cólon, reto e estômago
• Investigação publicada sobre o impacto da localização do tumor na sobrevivência ao cancro do cólon
• Membro da Associação Turca de Oncologia Médica

O Dr. Greenberg chefia o Departamento de Cirurgia Colorretal no Centro Médico Sourasky, liderando uma equipe de ponta para o tratamento do câncer de cólon.

• Mais de 35 anos de experiência de experiência como cirurgião abdominal
• Especialista em técnicas cirúrgicas abertas e minimamente invasivas
• Realiza a cirurgia de Whipple para casos complexos
• Ocupa um cargo de liderança sênior no Hospital Ichilov

O Dr. Elkhan Mammadov é oncologista clínico. Concentra-se no diagnóstico e tratamento do cancro, incluindo quimioterapia citotóxica, hormonoterapia, terapia direcionada (fármacos inteligentes) e imunoterapia.

Educação: Universidade Médica do Azerbaijão, MD (2004–2010). Universidade de Istambul, Faculdade de Medicina de Istambul, formação em Medicina Interna (2014–2019). Hospital Universitário Istanbul Medipol Mega, formação de subespecialidade em Oncologia Clínica (2019–2022).

Experiência: 5 anos em Medicina Interna. 3 anos em Oncologia Clínica.

Afiliações: Sociedade Turca de Oncologia Clínica. ESMO (Sociedade Europeia de Oncologia Clínica). ASCO (Sociedade Americana de Oncologia Clínica).

O Dr. Liu Shi Xin é vice-presidente do Ramo de Oncologia Radioterápica da Associação Médica Chinesa. Ele atua como Líder de Disciplina do Centro de Oncologia no Hospital Xiamen Humanity. O Dr. Liu é especializado em radioterapia de precisão para cânceres torácicos e abdominais. Ele é beneficiário do Subsídio Governamental Especial do Conselho de Estado por suas contribuições médicas.

• Altamente proficiente em IMRT, VMAT e SBRT para cânceres de pulmão e esôfago.
• Ex-presidente do Hospital Oncológico da província de Jilin.
• Premiado com a honra de Médico Nacional Famoso por suas contribuições notáveis à oncologia.
• Ocupa cargos de liderança no comitê de terapia de partículas da Associação Chinesa contra o Câncer.

A Dra. Mariam Abu Zeid é oncologista clínica nos hospitais oncológicos internacionais Shefaa Al Orman. Ela é certificada pela Sociedade Europeia de Oncologia Médica (ESMO). A Dra. Abu Zeid trata tumores sólidos e cânceres hematológicos. Ela possui doutorado (Ph.D.) em Oncologia Clínica e Medicina Nuclear pela Universidade Ain Shams.

• Administra quimioterapia, imunoterapia e tratamentos direcionados para vários tipos de câncer.
• Supervisiona ensaios clínicos oncológicos e gerencia toxicidades relacionadas ao tratamento.
• Coordena o atendimento ao paciente dentro de equipes multidisciplinares para estadiamento e diagnóstico complexos.
• Atua em um centro credenciado pela ESMO que trata aproximadamente 6.000 pacientes anualmente.

O Dr. Irfan Cicin é professor de Oncologia Médica no Hospital İstinye University Liv Topkapı. Especializa-se no tratamento de cancros complexos, incluindo glioblastoma, cancro do pulmão e tumores pancreáticos. É professor na Faculdade de Medicina da Universidade de Trakya. O Dr. Cicin serviu anteriormente como médico na Força Aérea Turca.

• Realiza terapias sistémicas como imunoterapia, quimioterapia e terapia hormonal.
• Trata uma vasta gama de condições, incluindo casos ginecológicos, ortopédicos e neuro-oncológicos.
• Especialista em HIPEC e quimioembolização para neoplasias hepáticas e abdominais.
• Trabalha num hospital universitário de 300 camas com 33 departamentos médicos.

O Dr. Ozden é especialista em cancro do cólon de estádio 4, com vasta experiência em oncologia médica.

• Licenciar-se no Programa Médico de Inglês da Universidade de Istambul
• Concluir a residência em Medicina Interna na Faculdade de Medicina de Cerrahpaşa
• Subespecializar-se em Oncologia Médica na Universidade de Kocaeli
• Praticar no Hospital Estatal de Şırnak e no Hospital Privado Safa de Bağcılar

O Dr. Muhammed Mustafa Atci é professor associado de Oncologia Médica no Liv Hospital Topkapı. Especializa-se no tratamento de cancros do cólon, mama, gástrico e pulmão. Anteriormente, serviu como Coordenador de Educação no Hospital Municipal Prof. Dr. Cemil Taşcıoğlu. O Dr. Atci é membro da Sociedade Americana de Oncologia Clínica (ASCO).

• Autor de 19 artigos revistos por pares sobre cancros gastrointestinais, torácicos e endócrinos.
• Publicou estudos sobre resultados de sobrevivência para cancro do cólon em estádio IIB no Journal of Chemotherapy.
• Investiga biomarcadores prognósticos usando exames PET/CT e volume tumoral metabólico.
• Trata casos oncológicos complexos na clínica universitária İstinye University.

A Dra. Maha Yahia é oncologista médica e hematologista nos Hospitais Oncológicos Internacionais Shefaa Al Orman. Serviu como médica com o posto de tenente-coronel no Corpo Médico das Forças Armadas Egípcias. A Dra. Yahia especializa-se no planeamento de tratamentos para cancros da mama, torácicos e gastrointestinais. Concentra-se em imunoterapia, terapia direcionada e protocolos complexos de quimioterapia.

• Ex-chefe da equipa de apoio à investigação clínica no Maadi AFMC.
• Formada no Instituto Nacional do Cancro da Universidade do Cairo em hemato-oncologia.
• Trata cancros geniturinários, ginecológicos e raros, além de doenças hematológicas.
• Trabalha num centro acreditado pela ESMO que trata 6.000 pacientes anualmente.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

_doctor_258_anos_ de pioneirismo em cirurgia minimamente invasiva de câncer de cólon – O Dr. de Lacy realizou mais de 15.000 procedimentos, incluindo mais de 1.000 anualmente no Hospital Quiron Barcelona.

• Primeiro cirurgião do mundo a desenvolver a técnica TaTME para câncer retal
• Presidente da Associação de Cirurgiões-Endoscopistas da Europa
• Palestrante sobre técnicas laparoscópicas avançadas em todo o mundo
• Pioneiro da cirurgia endoscópica transluminal (NOTES)

O Dr. Yaacov Lawrence é o Chefe de Oncologia Radioterápica no Centro Médico Sheba. Ele é especializado em radioterapia de precisão e neuro-oncologia. O Dr. Lawrence foi pioneiro na radiocirurgia do plexo celíaco para o controle da dor no câncer de pâncreas. Ele possui a designação FASTRO, uma das mais altas honrarias em sua especialidade.

• Lidera o Programa de Câncer Gastrointestinal no Centro Médico Sheba.
• Realiza radiocirurgia estereotática para tumores cerebrais e cânceres do sistema nervoso.
• Autor de mais de 280 publicações científicas sobre protocolos de radiação personalizados.
• Concluiu o treinamento de fellowship em oncologia radioterápica na Universidade Thomas Jefferson.

O Dr. Raanan Berger é o diretor do Centro de Câncer do Sheba Medical Center. Ele foi incluído na lista de "Melhores Médicos" da Forbes Israel em 2025. O Dr. Berger é especializado em oncologia geniturinária e trata tumores complexos de próstata com radioterapia. Ele completou um pós-doutorado no Dana-Farber/Harvard Cancer Institute.

• Chefia a unidade de pesquisa clínica focada em oncologia molecular.
• Coautor de mais de 20 artigos revisados por pares sobre câncer de próstata e mutações BRCA.
• Membro da Sociedade Americana de Oncologia Clínica (ASCO).
• Realiza terapia sistêmica e radioterapia em um hospital classificado entre os 10 melhores do mundo.

O Dr. Beni Boursi é um oncologista de destaque no Sheba Medical Center. Fundou o Grupo de Trabalho sobre Microbioma da ECOG-ACRIN. Especializa-se no tratamento de cancros gastrointestinais utilizando modulação microbiana inovadora. O Dr. Boursi é certificado em medicina interna e oncologia médica. Obteve o seu diploma de medicina com as mais altas distinções na Universidade de Tel Aviv.

• Concluiu estágios em oncologia na Universidade da Pensilvânia.
• Formou-se em oncologia médica no MD Anderson e na Mayo Clinic.
• Desenvolveu modelos preditivos para o diagnóstico precoce do cancro colorretal e pancreático.
• Publicou pesquisas sobre microbioma em oncologia na prestigiada revista Science.

O Dr. Emad Shash é um oncologista médico que participou em mais de 70 ensaios clínicos oncológicos. Ele atua como Diretor Médico do Hospital Integral de Câncer de Mama no NCI. O Dr. Shash é especializado em terapias sistêmicas, incluindo quimioterapia, terapia alvo e imunoterapia. Ele possui um diploma da JCI em Gestão de Qualidade Hospitalar e Segurança do Paciente.

• Membro votante do painel da ESMO e membro do comité da ASCO.
• Trata cancro da mama, ginecológico, geniturinário, torácico, gastrointestinal e cancros raros.
• Ex-médico investigador e líder médico na EORTC em Bruxelas.
• Trabalha no Shefaa Al Orman, um centro oncológico acreditado pela ESMO que trata 6.000 pacientes anualmente.

A Dra. Brenda Pastrana é uma cirurgiã oncológica certificada especializada em câncer de cólon no Hospital Galenia.

• Certificada pelo Conacem com credenciais válidas até 2030
• Membro da Sociedade Mexicana de Oncologia (SMEO)
• Professora universitária na Faculdade de Medicina da Universidad Anahuac desde 2020
• Formada no Centro Medico Nacional 20 de Noviembre Issste